Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 13.74% ...

Among significant research news last week, US biotech Allakos reported that it was dropping development of its urticaria ...

Sage Therapeutics rejects Biogen deal offer; Silvus Technologies considers sale/IPO; Allakos downsizes; MrBeast bids on ...

Cargo Therapeutics, a Bay Area biotech firm, is laying off half its staff after having to shut down a promising drug ...

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...